Aurobindo Pharma has reported results for fourth quarter (Q4) and year ended March 31, 2024.
The company has reported 10.28% fall in its net profit at Rs 578.67 crore for the quarter under review as compared to Rs 644.97 crore for the same quarter in the previous year. However, total income of the company increased by 12.31% at Rs 3,017.00 crore for Q4FY24 as compared Rs 2,686.42 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported 79.35% rise in its net profit at Rs 907.35 crore for fourth quarter ended March 31, 2024 as compared to Rs 505.91 crore for the same quarter in the previous year. Total income of the company increased by 16.77% at Rs 7,715.77 crore for Q4FY24 as compared Rs 6,607.87 crore for the corresponding quarter previous year.
For the year ended March 31, 2024, the company has reported 59.25% rise in its net profit at Rs 1,954.14 crore as compared to Rs 1,227.11 crore for the previous year. Total income of the company increased by 26.52% at Rs 11,261.70 crore for year under review as compared to Rs 8,900.92 crore for year ended March 31, 2023.
For the year ended March 31, 2024, on the consolidated basis, the company has reported 64.40% rise in its net profit at Rs 3,168.97 crore as compared to Rs 1,927.65 crore for the previous year. Total income of the company increased by 17.55% at Rs 29,559.25 crore for year under review as compared to Rs 25,145.97 crore for year ended March 31, 2023.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1777.65 |
Dr. Reddys Lab | 1194.55 |
Cipla | 1465.65 |
Lupin | 2043.30 |
Zydus Lifesciences | 944.25 |
View more.. |